The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial
Authors
Keywords
-
Journal
European Journal of Preventive Cardiology
Volume 21, Issue 3, Pages 299-309
Publisher
SAGE Publications
Online
2013-11-05
DOI
10.1177/2047487313510678
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease
- (2013) Regina Kunz et al. ANNALS OF INTERNAL MEDICINE
- Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
- (2012) Michael H. Alderman et al. HYPERTENSION
- Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy
- (2012) Sara S. Roscioni et al. Nature Reviews Nephrology
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction
- (2011) Scott D. Solomon et al. EUROPEAN HEART JOURNAL
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
- Serum Potassium and Outcomes in CKD: Insights from the RRI-CKD Cohort Study
- (2010) S. Korgaonkar et al. Clinical Journal of the American Society of Nephrology
- Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
- (2010) Y. Miao et al. DIABETOLOGIA
- Dual RAS Therapy Not on Target, but Fully Alive
- (2010) H.J. Lambers Heerspink et al. NEPHRON CLINICAL PRACTICE
- Risk of Hyperkalemia in Nondiabetic Patients With Chronic Kidney Disease Receiving Antihypertensive TherapyHyperkalemia in CKD Adults Using Antihypertensives
- (2009) Joy M. Weinberg ARCHIVES OF INTERNAL MEDICINE
- The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
- (2009) Lisa M. Einhorn et al. ARCHIVES OF INTERNAL MEDICINE
- Mechanisms of Impaired Potassium Handling With Dual Renin-Angiotensin-Aldosterone Blockade in Chronic Kidney Disease
- (2009) Richard A. Preston et al. HYPERTENSION
- Mechanisms in Hyperkalemic Renal Tubular Acidosis
- (2009) F. E. Karet JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease
- (2009) M. Frimodt-Moller et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
- (2008) Johannes FE Mann et al. LANCET
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started